Abstract
IntroductionOptimal pharmacological treatment of tuberculosis (TB) requires a multidisciplinary team, yet the hospital pharmacist’s role is unclear. We aimed to analyse hospital pharmacist-provided clinical pharmacy services (CPS) implementation in TB care.MethodA nationwide survey-based online cross-sectional study was conducted on hospital pharmacists in Indonesia from 1 November 2022 to 22 November 2022. Outcomes were the extent of pharmacists’ involvement in multidisciplinary TB care, TB-related CPS provided and views on TB-related CPS. The probability of pharmacists’ involvement in multidisciplinary TB teams was assessed using logistic regression.ResultsIn total, 439 pharmacists (mean age 31.2±6.22 years, 78% female) completed the survey. Thirty-six per cent were part of multidisciplinary TB care, and 23% had TB-related tasks. Adherence monitoring (90%) and drug use evaluation (86%) were the most conducted TB-related CPS. Pharmacists’ views on TB-related CPS implementation were generally positive, except for financial incentives. Work experience (OR 1.99, 95% CI 1.09 to 3.61), ever received TB-related training (OR 3.51, 95% CI 2.03 to 6.14) and specific assignments to provide TB-related CPS (OR 8.42, 95% CI 4.99 to 14.59) significantly increased pharmacist involvement in multidisciplinary TB care.ConclusionAround one-third of hospital pharmacists are part of multidisciplinary TB care, with medication adherence and drug use monitoring as primary tasks. Pharmacists’ experience, training, assignment to provide TB-related CPS and financial incentives are key elements for further implementation in multidisciplinary TB care. Pharmacists should proactively support current TB care and conduct operational research, sharing data with healthcare peers and fostering a collaborative multidisciplinary TB care team.
Subject
Pulmonary and Respiratory Medicine
Reference57 articles.
1. World Health Organization . Global tuberculosis report 2022. Geneva World Health Organization; 2022. Available: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022
2. World Health Organization . Implementing the end TB strategy: the essentials. Geneva World Health Organization; 2022. Available: https://www.who.int/publications/i/item/9789240065093
3. Clinical and economic burden of drug-susceptible tuberculosis in Indonesia: national trends 2017-19;Iskandar;Lancet Glob Health,2023
4. Whittlesea C , Hodson K . Clinical pharmacy and therapeutics. United Kingdom: Elsevier, 2019.
5. The impact of first-line anti-tubercular drugs' pharmacokinetics on treatment outcome: a systematic review;Sileshi;Clin Pharmacol,2021